Does Biktarvy Harm the Liver?
Biktarvy, a single-tablet HIV regimen combining bictegravir, emtricitabine, and tenofovir alafenamide, carries a boxed warning for lactic acidosis and severe hepatomegaly with steatosis. These rare but serious liver issues stem mainly from the tenofovir component, which can build up fat in the liver and impair its function, especially in patients with risk factors like hepatitis B or heavy alcohol use.[1][2]
Who Gets Liver Problems from Biktarvy?
Liver enzyme elevations (ALT/AST increases) occur in about 2-3% of patients in clinical trials, typically mild and resolving without stopping treatment. Discontinuation due to liver issues is under 1%. Patients with pre-existing liver disease, HBV/HCV coinfection, or obesity face higher risks—monitoring is standard, with tests every 3-6 months initially.[3][4]
What Happens with Hepatitis B Coinfection?
Biktarvy treats HBV via emtricitabine and tenofovir, but stopping it can trigger acute HBV flares with liver failure in up to 25% of cases. Symptoms include jaundice, dark urine, and abdominal pain; flares may be fatal. Guidelines recommend against using Biktarvy as sole HBV therapy and require HBV screening before starting.[1][5]
How Does It Compare to Other HIV Drugs on Liver Impact?
Biktarvy uses TAF, a safer tenofovir form than TDF (in older regimens like Truvada), with 4x lower plasma levels and less kidney/liver strain. Studies show TAF regimens like Biktarvy cause fewer ALT elevations than TDF-based ones (3% vs 5-7%). Still, integrase inhibitors like dolutegravir (Tivicay) may edge it out with even lower hepatotoxicity rates.[6][7]
When Should Liver Tests Be Done?
Baseline liver function tests are required before starting, then at 3 months, 6 months, and annually. More frequent checks apply for HBV carriers or rising enzymes. No routine imaging unless symptoms appear.[2][4]
Can Liver Damage Be Reversed?
Most cases reverse after dose adjustment or switching drugs. Persistent issues may need specialist input, like switching to non-tenofovir options (e.g., dolutegravir/lamivudine). Avoid alcohol and hepatotoxins during use.[3]
[1]: Biktarvy Prescribing Information (Gilead)
[2]: FDA Label for Biktarvy
[3]: GS-380-4030 Trial Data (NEJM)
[4]: DHHS HIV Guidelines: Liver Monitoring
[5]: EACS Guidelines on HBV Flares
[6]: TAF vs TDF Liver Safety (JAMA)
[7]: Gilead Trial 1489/1490 (Lancet)